Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute , Boston, MA, USA.
Department of Hematology, School of Medicine, Ankara University , Ankara, Turkey.
Expert Opin Biol Ther. 2020 Dec;20(12):1395-1404. doi: 10.1080/14712598.2021.1841747.
Although new drug classes have significantly extended survival of patients with multiple myeloma, they continue to experience multiple relapses and/or become refractory to treatment. Therefore, novel therapies and treatment combinations with different mechanisms of action are needed to improve the outcomes of patients with relapsed/refractory multiple myeloma.
Here, the authors review the published data regarding the development and clinical investigation of isatuximab, a CD38 monoclonal antibody, for treatment of patients with relapsed/refractory multiple myeloma. The mechanisms of action, clinical efficacy, and safety of isatuximab treatment are summarized.
Isatuximab is approved in combination with pomalidomide/dexamethasone for the treatment of adults with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Isatuximab displays a manageable safety profile, with infusion reactions being the most common adverse events. Isatuximab is currently being further evaluated in combination with other backbone regimens in relapsed/refractory and newly diagnosed multiple myeloma.
尽管新的药物类别显著延长了多发性骨髓瘤患者的生存时间，但他们仍会经历多次复发和/或对治疗产生耐药性。因此，需要新的治疗方法和具有不同作用机制的治疗组合来改善复发/难治性多发性骨髓瘤患者的预后。
作者在这里回顾了已发表的关于 CD38 单克隆抗体伊沙妥昔单抗治疗复发/难治性多发性骨髓瘤的开发和临床研究数据。总结了伊沙妥昔单抗治疗的作用机制、临床疗效和安全性。
伊沙妥昔单抗已获批准与泊马度胺/地塞米松联合用于治疗至少接受过两种先前治疗（包括来那度胺和蛋白酶体抑制剂）的复发/难治性多发性骨髓瘤成人患者。伊沙妥昔单抗的安全性特征易于管理，最常见的不良反应是输注反应。伊沙妥昔单抗目前正在复发/难治性和新诊断的多发性骨髓瘤中与其他骨干方案联合进行进一步评估。
